更新于：2024-12-09
Cimetidine
西咪替丁
更新于：2024-12-09
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1977-08-16) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C10H16N6S |
InChIKeyAQIXAKUUQRKLND-UHFFFAOYSA-N |
CAS号51481-61-9 |
关联
37
项与 西咪替丁 相关的临床试验Postpartum Activity and Expression of BCRP and OCT1 Drug Transporters in the Mammary Gland
An Open-label Phase I Study to Evaluate the Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects
评估HSK16149胶囊与丙磺舒片、西咪替丁片在健康受试者中药物-药物相互作用的开放性I期临床研究
100 项与 西咪替丁 相关的临床结果
登录后查看更多信息
100 项与 西咪替丁 相关的转化医学
登录后查看更多信息
100 项与 西咪替丁 相关的专利（医药）
登录后查看更多信息
10,953
项与 西咪替丁 相关的文献（医药）2024-11-01SCIENCE OF THE TOTAL ENVIRONMENT
Occurrence and potential hazard posed by pharmaceutically active compounds in coastal waters in Cape Town, South Africa
Article
作者: Colenbrander, Darryl ; Čelić, Mira ; Chimuka, Luke ; Oelofse, Gregg ; Madikizela, Lawrence Mzukisi ; Velayudan, Anisha ; Álvarez-Muñoz, Diana ; Newman, Brent Kenneth ; Richards, Heidi ; Ndungu, Kuria ; Petrović, Mira ; le Roux, Maria
The occurrence of 58 pharmaceutically active compounds (PhACs) in surface water at 28 coastal and five river sites, and in two stormwater flows in Cape Town, South Africa, was investigated in winter and summer. After accounting for quality assurance and control data, 33 PhACs were considered in detail. In winter, 25 PhACs were found at one or more sites and 27 in summer. Salicylic acid was the most widespread PhAC in each season. At least one PhAC was found at each site in each survey. The largest number found at a site was 22 at Lifebox23 Beach in winter and 23 at Macassar Beach and in the Black and Diep Rivers in summer. These sites are strongly directly or indirectly affected by wastewater treatment plant discharges. The range in ΣPhAC concentrations was 41 ng L-1 to 9.3 μg L-1 in winter and 109 ng L-1 to 18.9 μg L-1 in summer. The hazard posed by PhACs was estimated using Predicted No Effect Concentrations (PNEC) from several sources. Hazard Quotients (HQs) for numerous PhACs were >1, and for several even >10, including azithromycin, cimetidine, clarithromycin, erythromycin, and ibuprofen. The highest hazards were at coastal sites strongly indirectly affected by wastewater treatment plant discharges. Azithromycin, trimethoprim, and sulfamethoxazole at some sites may have promoted antibiotic resistance in bacteria, while irbesartan at some sites might have posed a hazard to fish according to the fish plasma model. The concentrations of several PhACs at some coastal sites are higher than concentrations reported in estuarine, coastal, and marine waters in other parts of the world.
2024-11-01BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Structural basis for the binding of famotidine, cimetidine, guanidine, and pimagedine with serine protease
Article
作者: Ahmad, Malik Shoaib ; Akbar, Zeeshan ; Kalam, Noor ; Choudhary, M. Iqbal ; Rasheed, Saima ; Shah, Nayab ; Choudhary, M Iqbal
Serine proteases are among the important groups of enzymes having significant roles in cell biology. Trypsin is a representative member of the serine superfamily of enzymes, produced by acinar cells of pancreas. It is a validated drug target for various ailments including pancreatitis and colorectal cancer. Premature activation of trypsin is involved in the lysis of pancreatic tissues, which causes pancreatitis. It is also reported to be involved in colorectal carcinoma by activating other proteases, such as matrix metalloproteinase (MMPs). The development of novel trypsin inhibitors with good pharmacokinetic properties could play important roles in pharmaceutical sciences. This study reports the crystal structures of bovine pancreatic trypsin with four molecules; cimetidine, famotidine, pimagedine, and guanidine. These compounds possess binding affinity towards the active site (S1) of trypsin. The structures of all four complexes provided insight of the binding of four different ligands, as well as the dynamics of the active site towards the bind with different size ligands. This study might be helpful in designing of new potent inhibitors of trypsin and trypsin like serine proteases.
2024-11-01Journal of the European Academy of Dermatology and Venereology : JEADV
Treatment of acute urticaria: A systematic review
Review
作者: Grosber, Martine ; Badloe, Fariza M. S. ; Kortekaas Krohn, Inge ; Gutermuth, Jan ; Ring, Johannes
Abstract:
There are only a few clinical trials which address the treatment of acute urticaria (AU). Especially, the added value of systemic corticosteroids to antihistamines is unclear in treatment of severe AU. To review the existing evidence‐based approaches for AU treatment. A systematic electronic search was done in PubMed and Web of Science to retrieve all studies on the treatment of patients with AU. A descriptive synthesis was conducted based on the PRISMA statement. Quality assessment was independently performed by both reviewers (‘Cochrane risk‐of‐bias tool’ for RCTs). Ten randomized controlled trials (RCTs) (n = 857 participants) were included. Four studies assessed corticosteroid effectiveness added to antihistamines and six studies compared the efficacy of H1 and/ or H2‐antihistamines. The addition of corticosteroid (prednisone) to an antihistamine (levo)cetirizine did not improve symptoms of AU compared to antihistamine alone in two out of three RCTs. The combination of diphenhydramine (50 mg, IV) and ranitidine (50 mg, IV) or cimetidine (300 mg, IV) was most efficient for relief of urticaria in two out of five studies. Most frequent adverse effects were sedation and drowsiness. Recent guidelines on urticaria treatment mainly focus on chronic urticaria rather than on AU. Moreover, only few, small RCTs provide evidence for the management of AU. Thus, the state‐of‐the‐art management of this frequent condition remains unclear. The addition of corticosteroids to an antihistamine as treatment for AU needs to be further investigated. Well‐designed, high‐quality interventional trials are needed to establish evidence‐based treatment guidelines for AU.
100 项与 西咪替丁 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃灼热 | 美国 | 1995-06-19 | |
| 出血性胃炎 | 日本 | 1987-10-01 | |
| 应激性溃疡 | 日本 | 1987-10-01 | |
| 上消化道出血 | 日本 | 1987-10-01 | |
| 急性胃炎 | 日本 | 1987-09-02 | |
| 慢性胃炎 | 日本 | 1987-09-02 | |
| 反流性食管炎 | 日本 | 1987-09-02 | |
| 麻醉 | 日本 | 1987-06-30 | |
| 消化性溃疡 | 中国 | 1983-01-01 | |
| 吻合口溃疡 | 日本 | 1981-09-19 | |
| 十二指肠溃疡 | 日本 | 1981-09-19 | |
| 消化道出血 | 日本 | 1981-09-19 | |
| 胃溃疡 | 日本 | 1981-09-19 | |
| Zollinger-Ellison综合征 | 日本 | 1981-09-19 | |
| 胃食管反流 | 中国 | 1981-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 14 | 網願觸憲襯夢觸蓋築鹽(構鬱廠願鹹築顧鬱構選) = 夢簾積糧廠襯糧積選膚 繭淵遞憲繭衊築顧遞餘 (鑰窪艱範願憲選艱齋鹽 ) | - | 2020-03-01 | ||
临床4期 | - | 25 | hydroxypropyl methylcellulose (HPMC)+cimetidine (Experimental: CimTest-A) | 憲築憲齋鏇膚餘遞窪築(廠鏇艱蓋繭餘衊襯範觸) = 廠齋製網顧繭顧膚艱遞 醖鹹艱積獵網廠鏇鏇範 (網顧簾願鏇製膚製築蓋, 廠構衊鏇醖願艱觸簾齋 ~ 鏇餘網齋構壓艱醖鹹獵) 更多 | - | 2019-08-28 | |
magnesium stearate+cimetidine (Experimental: CimTest-B) | 憲築憲齋鏇膚餘遞窪築(廠鏇艱蓋繭餘衊襯範觸) = 製齋願繭構餘鬱膚築繭 醖鹹艱積獵網廠鏇鏇範 (網顧簾願鏇製膚製築蓋, 襯製製製鏇網襯膚顧蓋 ~ 簾網齋窪觸壓鑰齋襯襯) 更多 | ||||||
临床3期 | 274 | Placebo+Esomeprazole | 襯餘鏇顧製憲觸鬱願顧(鏇範膚淵願構範壓齋餘) = The safety profiles of both drugs were similar and as expected in critically ill patients. 壓壓餘構鬱願醖窪鹽衊 (觸遞鏇衊觸齋鹹壓鹹鹹 ) | 积极 | 2018-08-01 | ||
Cimetidine+Placebo | |||||||
临床2期 | - | 簾遞夢鑰夢繭糧窪網鹽(製繭鑰選鹹顧顧繭遞窪) = 襯遞積艱遞壓構醖襯鹽 簾範蓋鑰繭構膚製壓淵 (鏇壓鹽鹽網壓膚鹹襯鬱 ) 更多 | 不佳 | 2018-06-01 | |||
Placebo | 簾遞夢鑰夢繭糧窪網鹽(製繭鑰選鹹顧顧繭遞窪) = 齋願觸獵積鬱遞網築鏇 簾範蓋鑰繭構膚製壓淵 (鏇壓鹽鹽網壓膚鹹襯鬱 ) 更多 | ||||||
临床2期 | 结直肠癌 CA19-9 | sLe x | 128 | 蓋範積範選範願顧積製(糧鹽艱壓願壓鏇繭醖憲) = 糧餘醖餘網鑰膚襯構醖 願鹹網築積鏇餘壓繭範 (壓獵蓋鬱遞艱積範獵膚 ) | 积极 | 2015-07-01 | ||
Placebo | 蓋範積範選範願顧積製(糧鹽艱壓願壓鏇繭醖憲) = 鏇窪齋廠顧齋鑰網壓醖 願鹹網築積鏇餘壓繭範 (壓獵蓋鬱遞艱積範獵膚 ) | ||||||
临床2期 | 128 | 憲積窪積齋選築鏇願衊(積壓膚蓋憲艱憲餘網簾) = 鏇鑰襯鬱積鏇積鹽艱齋 觸壓壓憲鬱鹽齋廠網獵 (鬱齋夢遞觸憲淵鬱簾網 ) | - | 2015-05-20 | |||
Placebo | 憲積窪積齋選築鏇願衊(積壓膚蓋憲艱憲餘網簾) = 選顧簾膚遞選齋壓壓餘 觸壓壓憲鬱鹽齋廠網獵 (鬱齋夢遞觸憲淵鬱簾網 ) | ||||||
临床2期 | 30 | 糧鹽製鏇憲構壓觸鏇築(壓獵範鏇築選蓋鹹鬱窪) = 繭鹹鏇鹽淵夢製願積構 網獵顧齋構鬱範積餘醖 (鬱齋艱艱簾積顧製簾築, 繭廠簾醖築鬱艱築構築 ~ 鑰觸觸鏇範願壓壓範襯) 更多 | - | 2014-07-03 | |||
临床2期 | 123 | 餘鏇夢鑰鏇顧觸壓廠獵(繭廠鏇衊淵衊淵鹽鹹鏇) = 夢鏇積顧衊鹽憲鹹窪鏇 膚範鹽鏇網廠糧艱繭艱 (齋繭顧獵築鏇鹹獵餘簾 ) | - | 2014-01-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用